Abstract Search

ba0006p186 | (1) | ICCBH2017

Is cherubism a systemic disease? Prospective study about 9 patients

Joly Aline , Maruani Gerard , Daire Valerie Cormier , Fauroux Brigitte , Berdal Ariane , Picard Arnaud , Coudert Amelie

Introduction: Cherubism is a rare pediatric disease with a maxillofacial localization caused by mutations of the SH3BP2 gene. Pathogenesis is well described in the Sh3bp2 KI mouse model that presents a systemic inflammatory and bone phenotypes maintained by TNFα and due to the presence of hypersensitive myeloid precursors. In human, the disease is usually described as a maxillofacial exclusive disease. The aim of our study was to explore the systemic phe...

0 shares

ba0003OP19 | Clinical | ECTS2014

Effect of subcutaneous recombinant human parathyroid hormone, rhPTH(1--84), on skeletal dynamics in hypoparathyroidism: findings from the 24-week replace and 8-week relay phase III clinical trials

Bilezikian John P , Maruani Gerard , Rothman Jeffrey , Clarke Bart L , Mannstadt Michael , Vokes Tamara , Lagast Hjalmar , Shoback Dolores M

see PP92....

0 shares

ba0003pp92 | Bone development/growth and fracture repair | ECTS2014

Effect of subcutaneous recombinant human parathyroid hormone, rhPTH(1--84), on skeletal dynamics in hypoparathyroidism: findings from the 24-week replace and 8-week relay phase III clinical trials

Bilezikian John P , Maruani Gerard , Rothman Jeffrey , Clarke Bart L , Mannstadt Michael , Vokes Tamara , Lagast Hjalmar , Shoback Dolores M

Hypoparathyroidism results in low bone turnover and increased bone mineral density (BMD). Replacing deficient PTH with rhPTH(184) has the potential to correct these skeletal abnormalities. To investigate the effect of rhPTH(184) on BMD and bone turnover markers (BTMs), data from two studies were assessed.REPLACE, a double-blind, multicenter, placebo-controlled study, randomized 134 patients with hypoparathyroidism to receive once-daily rhPTH(...

0 shares

Bone Abstracts

Is cherubism a systemic disease? Prospective study about 9 patients

Effect of subcutaneous recombinant human parathyroid hormone, rhPTH(1--84), on skeletal dynamics in hypoparathyroidism: findings from the 24-week replace and 8-week relay phase III clinical trials

Effect of subcutaneous recombinant human parathyroid hormone, rhPTH(1--84), on skeletal dynamics in hypoparathyroidism: findings from the 24-week replace and 8-week relay phase III clinical trials

BiosciAbstracts